Lexicon Pharmaceuticals 2008 Annual Report to Stockholders Available Online
March 13 2009 - 6:30AM
PR Newswire (US)
THE WOODLANDS, Texas, March 13 /PRNewswire-FirstCall/ -- Lexicon
Pharmaceuticals, Inc. (NASDAQ:LXRX), a biopharmaceutical company
focused on discovering and developing breakthrough treatments for
human disease, today made available its 2008 annual report to
stockholders on the Lexicon Pharmaceuticals corporate website at
http://www.lexpharma.com/. Hard copies are available, free of
charge, to Lexicon stockholders by contacting Lexicon's Investor
Relations Department at 281.863.3000. Lexicon has also provided the
annual report to the Securities and Exchange Commission. About
Lexicon Lexicon is a biopharmaceutical company focused on
discovering and developing breakthrough treatments for human
disease. Lexicon currently has five drug candidates in development
for autoimmune disease, carcinoid syndrome, diabetes, glaucoma and
irritable bowel syndrome, all of which were discovered by the
company's research team. The company has used its proprietary gene
knockout technology to identify more than 100 promising drug
targets. Lexicon has focused drug discovery efforts on these
biologically-validated targets to create its extensive pipeline of
clinical and preclinical programs. For additional information about
Lexicon and its programs, please visit http://www.lexpharma.com/.
Safe Harbor Statement This press release contains "forward-looking
statements," including statements relating to Lexicon's growth and
future operating results, discovery and development of products,
strategic alliances and intellectual property, as well as other
matters that are not historical facts or information. All
forward-looking statements are based on management's current
assumptions and expectations and involve risks, uncertainties and
other important factors, specifically including those relating to
Lexicon's ability to successfully conduct preclinical and clinical
development of its potential drug candidates, advance additional
candidates into preclinical and clinical development, obtain
necessary regulatory approvals, achieve its operational objectives,
obtain patent protection for its discoveries and establish
strategic alliances, as well as additional factors relating to
manufacturing, intellectual property rights, and the therapeutic or
commercial value of its drug candidates, that may cause Lexicon's
actual results to be materially different from any future results
expressed or implied by such forward-looking statements.
Information identifying such important factors is contained under
"Factors Affecting Forward-Looking Statements" and "Risk Factors"
in Lexicon's annual report on Form 10-K for the year ended December
31, 2008, as filed with the Securities and Exchange Commission.
Lexicon undertakes no obligation to update or revise any such
forward-looking statements, whether as a result of new information,
future events or otherwise. DATASOURCE: Lexicon Pharmaceuticals,
Inc. CONTACT: Jason Ray, Manager, Corporate Communications and
Investor Relations of Lexicon Pharmaceuticals, Inc.,
+1-281-863-3225, Web Site: http://www.lexpharma.com/
Copyright
Lexicon Pharmaceuticals (NASDAQ:LXRX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Lexicon Pharmaceuticals (NASDAQ:LXRX)
Historical Stock Chart
From Jul 2023 to Jul 2024